cOVID-19 vaccine: Unlike the Serum Institute of India's (SII) vaccine Covid- shield, Covaxin will be used only in 'clinical trial mode', where consent will be taken and side-effects monitored, the heads of AIIMS and ICMR, part of the National Covid-19 task force, told The Indian Express. Written by RAJENDRA GOKHALE | CHENNAI Dry run of Covid19 vaccination process at Duttabad primary heath centre in Saltlake Kolkata on Saturday January 02, 2021. T he indigenous vaccine developed by Bharat Biotech with the Indian Council of Medical Research (ICMR) will be used as a “back-up”, only if the country needs extra doses to vaccinate a large number of people, particularly given the possibility of a surge triggered by the UK variant. And, unlike the Serum Institute of India’s (SII) vaccine Covid shield, Covaxin will be used only in ‘clinical trial mode’, where consent will be taken and side-effects monitored, the heads of AIIMS and ICMR, part of the National Covid-19 task force,...